HISTORY

BACKGROUND
The clinical “syndrome” of CKD-MBD has been recognized as an important contributor to morbidity and mortality throughout all stages of CKD. In the past, research centers have traditionally and individually focused on some isolated aspects of this newly recognized entity. Nevertheless, CKD-MBD is a complex interaction of multiple disturbances finally resulting in heterogeneous sequelae. Thus, a common platform for educational, intellectual and personal-fellow exchange needed facilitate research in a field where many efforts are still needed.
It was felt that large scale cooperation between centers with special interest in these matters needed improvement in order to achieve a global and translational approach to pathophysiology, prevention and treatment of CKD-MBD. Research targets have not always met clinical needs and some urgent research targets have not still been adequately addressed, specially referring to important hard end-points.
HISTORY
Part of this kind of cooperation, such as exchange of expertise including fellow scholar and exchange programs started in 2010 as an international cooperative structure for centers with both scientific as well as clinical interests in CKD-MBD.

As a first step, four scientific symposia (Amsterdam 2010, Prague EDTA 2011, Barcelona 2011, Paris EDTA 2012), two Fellow Days – where young fellows had the opportunity to meet and interact with experts in CKD-MBD) and an additional Fellow Training Day 2011 at UDETMA (Atherothrombotic Disease Detection and Treatment Unit), Lleida (Spain), have already been organized.

A Supplement to Kidney International (2011) has been published by the core group as a summary report of their joint scientific interests and activities.

BOARD

Mathias Loberg Haarhaus (Sweden) – Chair
Daniel Cejka (Austria) – Vice Chair
Carlo Alfieri (Italy)
Martin H. de Borst (Netherlands)
Jordi Bover (Spain)
Etienne Cavalier (Belgium)
Maria Fusaro (Italy)
Mehmet Kanbay (Turkey)
Markus Ketteler (Germany)
Smeeta Sinha (United Kingdom)

JOIN THE WORKING GROUP

Being a ordinary member of the CKD-MBD Working Group means being part of a network which facilitates exchanges of in the field of interest of CKD-MBD and Bone Mineral disorders in CKD.

Becoming an ordinary member of the CKD-MBD Working Group is FREE OF CHARGE. Ordinary members must be ERA members and be persons with a proven interest in the research area covered by the WG. Exceptions are possible only for non-nephrologists.

By joining the CKD-MBD Working Group you will receive constant updates on the Working Group initiatives be included in the Directory of CKD-MBD Working Groups’ ordinary members and start networking with colleagues from all over the world.

Click here to join.
The ordinary membership application is subject to validation. Please allow some time for a quick administrative check before applying multiple times.

PUBLICATIONS

Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment
Kidney International, June 2021

Bone evaluation in paediatric chronic kidney disease: Clinical practice points from the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the ERA-EDTA
Nephrology Dialysis and Transplantation, November 2020

European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D
Nephrology Dialysis Transplantation, October 2020

Cinacalcet use in paediatric dialysis: a position statement from the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders Working Group of the ERA-EDTA
Nephrology Dialysis Transplantation, October 2019 –  Click here to watch the related NDT Author video

Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease
Clinical Kidney Journal, July 2018

Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population
The Lancet Diabetes & Endocrinology, October 16, 2017

Bone in CKD: why the ERA EDTA CKD-MBD working group organized a dedicated meeting?
Journal of Nephrology, September 2017

The role of phosphate in kidney disease
on behalf of the ERA–EDTA Working Group on Chronic Kidney Disease–Mineral and Bone Disorders and the European Renal Nutrition Working Group,
Nature Reviews Nephrology, November 2016

Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease
Journal of Nephrology, April 2017

The use of bone mineral density measured by dual energy X-ray absorptiometry (DXA) and peripheral quantitative computed microtomography in chronic kidney disease
Journal of Nephrology, September 2017

Update on the role of bone biopsy in the management of patients with CKD–MBD
Journal of Nephrology, August 2017

Evaluation of fracture risk in chronic kidney disease
Journal of Nephrology, April 2017

Circulating markers of bone turnover
Journal of Nephrology, May 2017

Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2–5 and on dialysis
Nephrology Dialysis Transplantation, May 2017

Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2–5 and on dialysis
on behalf of the European Society for Paediatric Nephrology Chronic Kidney Disease Mineral and Bone Disorders and Dialysis Working Groups.
Nephrology Dialysis Transplantation, July 2017

Vitamin D, a modulator of musculoskeletal health in chronic kidney disease
for the European Renal Nutrition (ERN) and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Working Groups of the European Renal Association–European Dialysis Transplant Association (ERA-EDTA)
Journal of Cachexia, Sarcopenia and Muscle, July 2017

Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative—a position paper
Nephrology Dialysis Transplant, March 2017

Vitamin D in Chronic Kidney Disease
edited by Pablo A. Ureña, Mario Cozzolino and MG Vervloet (Springer)

Magnesium-based interventions for normal kidney function and chronic kidney disease
Magnesium Research, December 2016

Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?
on behalf of ERA-EDTA Working Group on CKD-MBD and EUCALNET.
Nephrology Dialysis Transplantation,  2016

Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement.
Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) working group and the European Renal Best Practice (ERBP) advisory board.; Chronic Kidney Disease-Mineral Bone Disease CKD-MBD working group and the European Renal Best Practice ERBP advisory board.
Nephrology Dialysis Transplantation, March 15

Pro: cardiovascular calcifications are clinically relevant.
Nephrology Dialysis Transplantation, February 2015

Opponent’s comments.
Nephrology Dialysis Transplantation, February 2015

Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet)
Clinical Kidney Journal,  July 2015

Mineral Bone Disorder Is a Key Player in Chronic Kidney Disease
Seminars in Nephrology, November 2014

UPDATES FROM RECENT PUBLICATIONS IN THE FIELD

CKD-MBD related publications in the ERA journals

(more reports on CKD-MBD related publications are available at the botton of this section)

The ERA acknowledges the high clinical and scientific relevance of the CKD-MBD syndrome, reflected by several key publications in the journals of our society. We hereby summarize the content of several recent important papers, providing a link to their abstracts.

From January to July 2022, 21 CKD-MBD related articles, including editorial comments and experimental studies, have been published; 11 in Nephrology Dialysis and Transplantation and 10 in the Clinical Kidney Journal (some were previously commented after publication in advanced form).

1)  Again, many reports dealt with vascular calcification (VC) and/or calciphylaxis. N. Seyahi et al (Clin Kidney J 15 (1): 101-108) examined coronary artery calcification (CAC) progression and long-term cardiovascular outcomes in kidney transplant (KT) recipients. They found that CAC at baseline and CAC progression robustly predicted the risk of death and cardiovascular events in these patients. B. Van Berkel et al (Clin Kidney J 15 (2): 295-302) aimed to define the prevalence, progression and implications of breast artery calcification (BAC) in female patients with CKD across various stages [CKD G2–5D-5T).  The role of magnesium to prevent CKD–associated vascular calcification was reviewed by A.D. ter Braake et al (Nephrol Dial Transplant 37 (3):421-429), and experimental studies performed by NHJ Leenders et al (Nephrol Dial Transplant 37 (6):1049-1058) demonstrated that increased dietary magnesium only inhibited abdominal vascular calcification in an experimental animal model of CKD in vivo.  G. Wasilewski et al  (Nephrol Dial Transplant 37 (4):652-662) described that only the combination of high vitamin K2 with phosphate binder treatment significantly attenuated VC in an experimental model of kidney failure with vitamin K deficiency, Guillén-Olmos et al (Clin Kidney 15 (4):663-671)analyzed their local series of calciphylaxis in KT recipients (largest to date), emphasizing that calciphylaxis can still occur after KT, in many cases during the first year and in patients with a good renal function. An associated editorial on the epidemiology and pathogenesis of calciphylaxis in different patient populations, also discussing recent findings for its therapeutic management, was reported by M.A. Podestà et al (Clin Kidney J 15 (4):611-614). A successful treatment of calciphylaxis with vitamin K in a patient on haemodialysis was reported by Z. Wajih and R. Singer (Clin Kidney J 15 (2):354-356). S. Sinha et al (Clin Kidney J 15 (1):136-144) described the design of the Phase 3 CALCIPHYX clinical trial which will examine the efficacy and safety of SNF472 in patients who have ulcerated calciphylaxis lesions.

2) Regarding cardiovascular (CV) events, M. Epstein and M. Freundlich (Nephrol Dial Transplant 37 (2): 211-222) reviewed the intersection between mineralcorticoid receptor activation and the FGF23-Klotho cascade, potentially promoting both renal and CV injury. H. Kim et al (Clin Kidney J 15 (1):119-127) reported that total hip- and and femur neck-low bone mineral density was associated with coronary arterial calcification progression and incident major adverse CV events (after adjusting for total hip T-score) in patients with CKD G1-5. D.A. Jaques et al al (Clin Kidney J 15 (6):1188-1195) described the association between femoral neck-bone mineral density and both mortality and fracture risk in patients receiving renal replacement therapy. Smoking was also shown as a significant risk factor for any fracture requiring hospitalization in japanese haemodialysis patients by M. Wakasugi et al (Nephrol Dial Transplant 37 (5):950-959). Wu P-S et al (Nephrol Dial Transplant 37 (6):1162-1170) showed that osteoprotegerin predicted CV events in haemodialysis patients, independently of cytokine activity, as opposed to other bone-associated proteins. Finally, osteocrin, another bone-derived humoral factor, was reported to exert a renoprotective role in ischemia-reperfusion injury in an experimental mice model conducted by Y. Nishiguchi et al (Nephrol Dial Transplant 37 (3):444-453).

3) P. Ureña-Torres et al (Nephrol Dial Transplant 37 (4):613-616) commented on a report by M. Bozic et al  (Nephrol Dial Transplant 37 (4):663-672) regarding the independent effects of hyperphosphatemia and secondary hyperparathyroidism (SHPT) on CKD progression and CV events. Clustering phosphate and iron-related markers and prognosis in dialysis patients were studied by H. Morooka et al (Clin Kidney J 15 (2): 328-337) using unsupervised machine learning methods. Authors found that the use of phosphate binders was associated with a lower risk of all-cause death in two clusters which were characterized by older age and higher prevalence of diabetes mellitus, among other factors.  The pharmacogenetic role of vitamin D-binding protein and vitamin D receptor polymorphisms in the treatment response of dialysis patients with SHPT was reviewed in a research letter by R. de Alarcón et al  (Nephrol Dial Transplant 37 (4):792-795). A. Iyengar et al (Nephrol Dial Transplant 37 (2):326-334) reported that intensive treatment with oral cholecalciferol in children with CKD as daily, weekly or monthly regimens achieved similar calcidiol concentrations without toxicity. Both FGF-23 and klotho concentrations significantly increased. Children with glomerular disease required higher doses of colecalciferol. Finally, A.S. Shankar et al (Nephrol Dial Transplant 37 (1):190-193) described vitamin D metabolism in human kidney organoids.

4) Finally, abstracts and contents of the 59th ERA-EDTA Congress 2022 can be found at the 2022 Nephrol Dial Transplant Supplement # 3

Jordi Bover and Sandro Mazzaferro

on behalf of the CKD-MBD Working Group

Acknowledgement: Dr. Elisabeth Massó for her valuable assistance.

Visit also:

CKD-MBD related publications July to December 2021

CKD-MBD related publications January to June 2021

CKD-MBD related publications July to December 2020

CKD-MBD related publications January to June 2020

CKD-MBD related publications July to December 2019

More ‘CKD-MBD related publications’ reports are available in the ‘Newsletters’ section and accessible by clicking the pertaining newsletter link.

ONGOING PROJECTS

  • EUropean Renal OsteoDystrophy (EUROD):  This bone-biopsy network aims at joining nephrologists, endocrinologists and pathologists (Coordinator: Pieter Evenepoel). It is expected to collect the largest possible bone samples to be examined homogeneously, in order to improve knowledge on the role of bone in systemic disease CKD-MBD risk prediction score development. A web based registry, educational activities, training fellowships are part of the activities carried out by the group. Steering Committee: P. Evenepoel, M. Vervloet, S. Mazzaferro, P. D’Haese, J. Bacchetta, J. Cannata-Andia, A. Ferreira, M. Haarhaus, MH Lafage Proust, S. Salam S, G. Spasovski.
  • Concerted Action in Renal Osteosdystrophy (CAiRO): This project consists of a population-based cohort study and a pilot biomarker study. It builds on unique epidemiological resources and cutting-edge analytical expertise, already available within the European-ROD (EUROD) initiative.
  • European Calciphylaxis registry (Eucalnet): ongoing. More updates will be posted soon.
  • CKD-MBD risk prediction score development: project aims at evaluating data from large registries to develop a score to identify independent risk of several CKD-MBD phenotypes.
  • CKD-MBD was invited by ESPN (chaired by Dr Justine Bacchetta) to join the committee to develop the guideline for the use of calcimimetics in children. Read more.
  • CKD-MBD phenotypes and all cause mortality. Collaboration with EuroDOPPS. Steering committee: M. Vervloet, Z. Massy, M. Cozzolino, A. Bellasi, T. Hoekstra. The analysis has been run by Dr D. Siriopol (Romania).

WEBCASTS

5th European Renal Osteodystrophy (EUROD) Winter Meeting – January 20-21, 2022

Click here to watch the webcast of the event


Bone biopsy: when and how – January 11, 2022
ERA WG e-seminar series #17 – organised by CKD-MBD
Click here to watch the webcast of the event

 


Treatment of secondary hyperparathyroidism in non-dialysis CKD – November 2, 2021

ERA WG e-seminar series #13 – organised by CKD-MBD
Click here to watch the webcast of the event


How to limit vascular calcification and treat calciphylaxis – February 18, 2021
ERA WG e-seminar series #2 – organised by CKD-MBD
Click here to watch the webcast of the event


4th European Renal Osteodystrophy (EUROD) Winter Meeting – January 14-15, 2021

Click here to watch the webcast of the event


Nephrology Virtual Preceptorship: Fracture Prevention in CKD – December 4, 2020
Click here to watch the webcast of the event

PAST ACTIVITIES

5th European Renal Osteodystrophy (EUROD) Winter Meeting – January 20-21, 2022
Click here to watch the webcast of the event

4th European Renal Osteodystrophy (EUROD) Winter Meeting – January 14-15, 2021
Click here to watch the webcast of the event

Nephrology Virtual Preceptorship: Fracture Prevention in CKD–  December 4, 2020
Click here to watch the webcast of the event

3rd European Renal Osteodystrophy (EUROD) Winter meeting – January 18, 2020 – Leuven, Belgium

The challenge of osteoporosis in CKD – January 18, 2019 – Leuven, Belgium

EURECA-m and CKD-MBD meeting – September 13-15, 2018 – Thessaloniki, Greece

The role of bone biopsy in clinical practice – January 19, 2018 – Leuven, Belgium

The parathyroid hormone (PTH) day in chronic kidney disease (CKD) from bench to bedside – September 8, 2017 – Paris, France

The Bone in Chronic Kidney Disease Symposium – September 23, 2016 – Amsterdam, Netherlands

NEWSLETTERS

CKD-MBD Newsletter #24, 2022

CKD-MBD Newsletter #23, 2022

CKD-MBD Newsletter #22, 2021

CKD-MBD Newsletter #21, 2021 – including CKD-MBD related publications in the field (January – June 2021)

CKD-MBD Newsletter #20, 2021 – including CKD-MBD related publications in the field (January – June 2020 and July to December 2020)

CKD-MBD Newsletter #18, 2019

CKD-MBD Newsletter #17, 2019

CKD-MBD Newsletter #16, 2019  – including CKD-MBD related publications in the field (July – December 2019)

CKD-MBD Newsletter #14-15, 2018

CKD-MBD Newsletter #13, 2018

CKD-MBD related publications #12 (Nephrol Dial Transplant and Clin Kidney J)

CKD-MBD Newsletter #11, 2018

CKD-MBD Newsletter #10, 2018
CKD-MBD related publications #10 (Nephrol Dial Transplant and Clin Kidney J)

CKD-MBD Newsletter #9 (1), 2018

CKD-MBD related publications #9 (Nephrol Dial Transplant and Clin Kidney J)

CKD-MBD Newsletter #8 (2), 2017
CKD-MBD related publications #8 (Nephrol Dial Transplant and Clin Kidney J)

CKD-MBD Newsletter #7 (1), 2017
CKD-MBD related publications #7 (Nephrol Dial Transplant and Clin Kidney J)

CKD-MBD Newsletter #6 (2), 2016
CKD-MBD related publications #6 (Nephrol Dial Transplant and Clin Kidney J)

CKD-MBD Newsletter #5 (1), 2016
CKD-MBD related publications #5 (Nephrol Dial Transplant and Clin Kidney J) 

CKD-MBD Newsletter #4 (2), 2015
CKD-MBD related publications #4 (Nephrol Dial Transplant and Clin Kidney J) 

CKD-MBD Newsletter 3, 2015
CKD-MBD related publications #3 (Nephrol Dial Transplant and Clin Kidney J)

CKD-MBD Newsletter 2, 2014

CKD-MBD Newsletter 1, 2013